1. Home
  2. FMC vs RAPP Comparison

FMC vs RAPP Comparison

Compare FMC & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FMC Corporation

FMC

FMC Corporation

N/A

Current Price

$8.30

Market Cap

1.3B

Sector

Industrials

ML Signal

N/A

Logo Rapport Therapeutics Inc.

RAPP

Rapport Therapeutics Inc.

N/A

Current Price

$30.87

Market Cap

1.5B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
FMC
RAPP
Founded
1910
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.5B
IPO Year
1994
2024

Fundamental Metrics

Financial Performance
Metric
FMC
RAPP
Price
$8.30
$30.87
Analyst Decision
Buy
Strong Buy
Analyst Count
17
14
Target Price
$13.26
★ $63.04
AVG Volume (30 Days)
★ 4.1M
410.4K
Earning Date
10-29-2026
11-05-2026
Dividend Yield
★ 3.59%
N/A
EPS Growth
N/A
★ 24.34
EPS
N/A
★ N/A
Revenue
★ $4,727,800,000.00
N/A
Revenue This Year
$3.22
N/A
Revenue Next Year
$4.11
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.42
$23.75
52 Week High
$31.30
$52.93

Technical Indicators

Market Signals
Indicator
FMC
RAPP
Relative Strength Index (RSI) 30.46 27.01
Support Level N/A $26.08
Resistance Level $12.37 $31.57
Average True Range (ATR) 0.44 2.30
MACD -0.07 -0.25
Stochastic Oscillator 3.33 12.40

Price Performance

Historical Comparison
FMC
RAPP

About FMC FMC Corporation

FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Share on Social Networks: